SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists, which have been known to prevent CKD progression, have been reimbursable for patients with diabetes in Korea since 2014 and 2015, respectively [2,3]. Here, SLC5A2 is linked to chronic kidney disease.